certainly not novices with the FDA. MSB is an expert at failing with the FDA. 2 CRLs for the same indication, how many trials failure of endpoint. Although I do recall some success for an IND in MSPCs in LVAD GI bleeding.
Ann: Mesoblast Type A Meeting with FDA, page-78
-
- There are more pages in this discussion • 497 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.526M | 3.824M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 473 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 18161 | 6 |
View Market Depth
| Last trade - 15.59pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |